Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase IIc Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Recombinant Human Thymosin Beta 4 Injection (NL005) in Patients With Acute Myocardial Infarction

NCT07586865 is registered in ClinicalTrials.gov with Beijing Northland Biotech. Co., Ltd. as lead sponsor.

NCT NCT07586865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07586865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase IIc Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Recombinant Human Thymosin Beta 4 Injection (NL005) in Patients With Acute Myocardial Infarction
Lead sponsor
Beijing Northland Biotech. Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 18, 2026
Completion date
May 17, 2028
Enrollment
189 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction (ami), acute myocardial infarction of anterior wall, acute myocardial infarction of left ventricle, acute myocardial infarction with st elevation, acute myocardial infarction with st segment elevation